H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Sol-Gel Technologies Ltd (NASDAQ: SLGL) today and set a price target of $21. The company’s shares closed yesterday at $7.21, close to its 52-week low of $6.03.
“We have valued Sol-Gel based on a discounted cash flow (DCF)-based analysis. This yields a value of $102M for TWIN, assuming a 50% probability of success, and a $323M valuation for VERED, assuming a 60% probability of success.”
According to TipRanks.com, Selvaraju is a 1-star analyst with an average return of 0.0% and a 35.6% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, Bausch Health Companies Inc, and Synergy Pharmaceuticals Inc.
Currently, the analyst consensus on Sol-Gel Technologies Ltd is a Moderate Buy with an average price target of $21.
The company has a one-year high of $16.48 and a one-year low of $6.03. Currently, Sol-Gel Technologies Ltd has an average volume of 28.49K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Sol-Gel Technologies Ltd. a clinical-stage dermatology company, which focuses on identifying, developing and commercializing topical dermatological drug products for the treatment of skin diseases. Its products include VERED, TWIN and SIRS-T. The company was founded by David Avnir and Alon Seri-Levy on October 28, 1997 and is headquartered in Ness Ziona, Israel.